Abstract
COVID-19 pandemic has changed the world and will keep us breathless for some time, still. Soon after the start of the disease in Wuhan and later in Italy and Spain, it became clear, that thromboses of arteries and veins played an important role in the severe cases.
The present article parts from the hypothesis, that patients suffering from COVID-19 could benefit from low molecular weight heparin (LMWH) in prophylactic dose or aspirin, if applied in early stages of the disease. LMWH prevent venous and ASS arterial thromboses. Different study approaches are proposed in the article. The difficulties to run a study like this, applying anti aggregation or anticoagulation to patients in early stages of SARS-CoV-2 infection are discussed, especially considering, that the medicaments are cheap and no industry will have any interest in sponsoring.
Most of the studies in corona disease are run in hospitals, where everybody fights to save critically ill patients. Very little investigation was done until now in pre-clinic patients. Mostly, because in lot of countries the testing was performed when admitted to hospital. Perhaps – even without a study – the evidence of thrombosis in the disease progression should lead to a D-Dimer testing after infection. The German Society of Thrombosis and Haemostasis Research (GTH) has recommended to consider administering heparin generously in COVID-19 ambulatory patients already in April 2020. Thus, in patients with little symptoms it would be possible to start early with LMWH in prophylactic dose in case of increased D-Dimer.
Key words
Corona pandemic - COVID-19 - thrombosis - symptom prevention - heparin - ASA
Schlüsselwörter
Corona - Thrombose - Vorbeugung der Symptomentwicklung - Pandemie COVID-19 - Heparin - ASS
